#biotech-disruption

[ follow ]
#patent-cliffs #ai-impact #large-cap-biotech #drug-pricing-reform #pharmaceutical-innovation
Healthcare
from24/7 Wall St.
4 days ago

Josh Brown: Biotech growth stocks immune to disruption risk

Large-cap biotech companies resist overnight AI-style disruption due to lengthy FDA approval processes, but face distinct slow-motion threats from patent cliffs, biosimilar competition, and drug pricing reform.
fromFast Company
6 months ago

Bet on the big idea-the only way to change the world

But at the time, his skepticism represented a familiar story: Bold, visionary ideas are met with resistance and fear from industries entrenched in conventional wisdom. Yet, time and again, we've seen how disruptors use technology and sheer conviction to rewrite the rules and yield transformative outcomes. In the last decade alone, this played out across industries like transportation, aerospace, and defense-from electric vehicles challenging Detroit to reusable rockets shattering the assumption of expendable space travel.
Medicine
[ Load more ]